Liquid Biopsy Industry

The global liquid biopsy market size was estimated at USD 10.42 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 11.60% from 2024 to 2030. The market for liquid biopsy is witnessing growth due to factors such as the growing prevalence of cancer, technological advancements in cancer diagnostics, and rising preference for minimally invasive cancer diagnostics. Moreover, ongoing research for liquid biopsy assays and tests, aided with the rising adoption and development of multi-cancer early detection tests,  provides opportunity for growth of overall market.

For various applications, such as breast, colorectal, ovarian cancer, non-small-cell lung cancer, and prostate cancer, liquid biopsy is used for diagnostics & screening, making it a vital tool. After various studies and speculations, it has been derived that liquid biopsy technique could provide an improved diagnostic outcome. Data suggests the use of screening techniques on high-risk patients who have an ancestral history of cancer. Moreover, over the past several years, studies have shown positive outcomes of liquid biopsy platforms. The government and various regulatory bodies have also shown interest in the area by promoting multiple breakthrough devices for rapid development of the technology.

However, amid the pandemic, several companies have adopted various strategic initiatives for providing safe & easy in-home access for liquid biopsy tests. For instance, in November 2020, NeoGenomics, Inc. announced the launch of a mobile phlebotomy service for liquid biopsy tests, including InvisionFirst and NeoLAB. The company offers its service through two phlebotomy companies, Metro Health Staffing LLC and ExamOne, for broad geographic coverage to ensure tests are performed efficiently.

Gather more insights about the market drivers, restrains and growth of the Global Liquid Biopsy market

Liquid Biopsy Market Segments Highlights:

Technology Insights

The multi-gene-parallel analysis (NGS) segment held the largest market revenue share of 75.68% in 2023 and is anticipated to grow at the fastest CAGR over the forecast period. NGS technology allows detection of various tumor-causing mutations and identification of potential emergence of post-treatment resistance mechanisms from pre-existing clones. Rapid developments in NGS technology have led to significant cost reductions in sequencing with high accuracy. Furthermore, key players operating in the market are developing innovative products to meet growing demand for diagnosis and maintain their position with an expanded product portfolio, thus driving the market growth. For instance, in January 2023, Agilent Technologies collaborated with Quest Diagnostics to provide access to Agilent Resolution ctDx FIRST, an NGS liquid biopsy test in the U.S.

Biomarker Insights

Circulating Nucleic Acids biomarker segment held the largest market share of 35.96% in 2023,attributable to widespread applications associated with ctDNA in liquid biopsy. Translational cancer researchers are identifying ctDNA from tumors using liquid biopsy. The discovery of ctDNA offers new opportunities in future liquid biopsy applications for cancer diagnosis by acting as a possible biomarker. ctDNA has been suggested as an alternative source in cancer patients for molecular profiling of tumor DNA, as opposed to invasive techniques. A new technique for early detection and monitoring of cancer has been made possible by the aberrant ctDNA identification from cancer cells.

Application Insights

Cancer application segment dominated the overall market with a revenue share of 86.26% in 2023, owing to rising adoption of liquid biopsy in detection of cancer aided by the rising prevalence of cancer globally. Liquid biopsy technology is one of the most evolving technologies in diagnostics and has made considerable headway in recent years, showing a significant growth in adoption in clinical applications. This approach is a fast-emerging precision oncology tool that allows for longitudinal monitoring and less invasive molecular diagnostics for therapy purposes. Furthermore, in June 2022, Elypta raised USD 21 million for development of MCED test with LEVANTIS-0087A study in progress for MCED.

End-use Insights

The hospitals and laboratories end-use segment dominated the market in 2023 with a revenue share of 42.33% in 2023. Hospitals are preferred for care due to availability of various services under one roof. The benefit of hospitals conducting cancer diagnosis is that they can offer results for tests even in emergencies. Liquid biopsy is helping doctors by giving them a highly precise cancer diagnosis in a shorter turnaround time, thereby reducing the treatment lag time. Cancer patients in hospitals undergo routine monitoring for analysis of resistance to treatment.

Clinical Application Insights

Therapy selection segment dominated the overall market in 2023 with a revenue share of 33.76%. The market's growth is attributed to selection of treatment options that can be affected by liquid biopsies to improve patient outcomes. Cancer is the second leading cause of mortality in the U.S. and most expensive disease to cure. Several advancements in cancer detection and biomarkers have been developed to aid the study of cancer progression and creation of successful treatment options.

Product Insights

The instruments product segment dominated the market in 2023 with a revenue share of 46.47%, attributed to the launch of new instruments and the advancement of existing products. For instance, in 2022, Tempus added xF+, a liquid biopsy panel made of 523 genes, a brand-new non-invasive test that focuses on pathogenic mutations in cfDNA, to its array of comprehensive genomic profiling services.

Sample Type Insights

Blood sample segment held the largest market share of 71.69% in 2023 and is projected to maintain its dominance over the forecast period. Blood-based liquid biopsy has remarkable advantages over traditional biopsy methods. Blood-based liquid biopsies are non-invasive, painless, and have no risk. In addition, it reduces time taken and cost for diagnosis. Exomes, CTCs, cfDNAs, and microvesicles in a blood sample can be detected, thus increasing adoption of blood-based liquid biopsy.

Regional Insights

North America dominated the market with a revenue share of 50.76% in 2023, owing to high cancer prevalence, rapid technological advancements, and growing government initiatives. Moreover, the market is led by the U.S. owing to more investments and presence of several biotechnology companies developing advanced tests.

Liquid Biopsy Market Report Segmentation

Grand View Research has segmented the global liquid biopsy market report based on sample type, biomarker, technology, application, end-use, clinical application, product, and region:

Liquid Biopsy Sample Type Outlook (Revenue, USD Million, 2018 - 2030)

• Blood Sample
• Others

Liquid Biopsy Biomarker Outlook (Revenue, USD Million, 2018 - 2030)

• Circulating Tumor Cells (CTCs)
• Circulating Nucleic Acids
• Exosomes/ Microvesicles
• Circulating Proteins

Liquid Biopsy Technology Outlook (Revenue, USD Million, 2018 - 2030)

• Multi-gene-parallel Analysis (NGS)
• Single Gene Analysis (PCR Microarrays)

Liquid Biopsy Application Outlook (Revenue, USD Million, 2018 - 2030)

• Cancer
• Reproductive Health
• Others

Liquid Biopsy End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals and Laboratories
• Specialty Clinics
• Academic and Research Centers
• Others

Liquid Biopsy Clinical Application Outlook (Revenue, USD Million, 2018 - 2030)

• Therapy Selection
• Treatment Monitoring
• Early Cancer Screening
• Recurrence Monitoring
• Others

Liquid Biopsy  Product Outlook (Revenue, USD Million, 2018 - 2030)

• Instruments
• Consumables Kits and Reagents
• Software and Services

Liquid Biopsy  Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America
  • US
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Key Companies & Market Share Insights

The presence of pipeline products in the liquid biopsy segment that are expected to launch in the coming years is anticipated to drive the market growth over the forecast period.

• In November 2023, Illumina Inc. announced the new TruSight Oncology 500 ctDNA v2, a new generation of its liquid biopsy assay for genomic profiling.
• In January 2023, Agilent Technologies, Inc. acquired Avida Biomed. This initiative is expected to provide it with rapid growth in the diagnostics and clinical research markets.

Key Liquid Biopsy Company Insights

• ANGLE plc
• Oncimmune Holdings PLC
• Guardant Health
• Myriad Genetics, Inc.
• Biocept, Inc.
• Lucence Health Inc.
• Freenome Holdings, Inc.
• Hoffmann-La Roche Ltd.
• QIAGEN
• Illumina, Inc.
• Thermo Fisher Scientific, Inc.
• Epigenomics AG

Order a free sample PDF of the Liquid Biopsy Market Intelligence Study, published by Grand View Research.